The occlusion-free survival at 12 , 24 , and 36 months was significantly higher in the AZA group ( 91 % , 81 % , and 72 % , respectively ) than in the mesalazine group ( 64.7 % , 35.3 % , and 23.5 % , respectively ; P < 0.05 for all comparisons ) .